Johnson & Johnson (JNJ)
Johnson & Johnson beats quarterly revenue estimates, maintains full-year outlook
Johnson & Johnson (NYSE:JNJ) reported first-quarter results on Tuesday that beat Wall Street expectations for revenue, driven by solid growth across its pharmaceutical and medical technology businesses. The healthcare conglomerate posted revenue of $24.06 billion for the quarter, up 9.9% from a year earlier and above analysts' estimates of $23.61 billion.
Johnson & Johnson (JNJ) Surpasses Q1 Earnings and Revenue Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.7 per share, beating the Zacks Consensus Estimate of $2.67 per share. This compares to earnings of $2.77 per share a year ago.
J&J raises guidance for 2026 on strong start to the year
The healthcare giant saw sales of medications, which include Darzalex and Tremfya, increase 11% in the first three months of the year
Growth vs. Stability: Lilly and J&J's 2026 Investment Face-Off
JNJ edges out LLY in a tight pharma showdown, backed by stronger valuation and stock performance despite Lilly's explosive GLP-1-driven growth.
Johnson & Johnson Q1 Earnings Preview: Time To Sell The Rally?
Johnson & Johnson stock is up 17% YTD and over 60% in the past twelve months, reflecting renewed investor confidence but also raising concerns about the sustainability of the rally. In this update on J&J - my first in nearly two years – I'll provide a brief preview of the first-quarter earnings report expected on Tuesday. More importantly, however, I will provide an update on JNJ's drug pipeline and growth prospects.
Should You Buy, Sell or Hold JNJ Stock Ahead of Q1 Earnings?
JNJ approaches Q1 results with strong drug growth and MedTech momentum. However, rising biosimilar competition and pricing pressures cloud the outlook.
Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to Know
Johnson & Johnson (JNJ) closed at $241.3 in the latest trading session, marking a +1.21% move from the prior day.
Johnson & Johnson: Success In Multiple Myeloma Underpins $25B In Growth By 2030
Johnson & Johnson earns a Buy rating, driven by the FDA approval of its Tecvayli and Darzalex Faspro combination for R/R multiple myeloma, delivering best-in-class efficacy. This combination therapy achieved an 83.4% 36-month progression-free survival rate, significantly outperforming the control arm and expanding JNJ's addressable market. JNJ's oncology pipeline, especially in hematology, is positioned to offset Stelara's LOE, targeting $50B in oncology sales and $125B total revenue by 2030.
JNJ Q1 MedTech Preview: Key Drivers and China Headwinds to Watch
JNJ's MedTech unit rides cardiovascular strength and new product adoption, but China headwinds loom ahead of its Q1 earnings release.
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Here's Why You Don't Bet Against This Dividend King
Markets have delivered plenty of twists lately, with inflation cooling but growth uneven and volatility still lurking around every earnings corner.
